Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
Rhea-AI Summary
Iridex (Nasdaq: IRIX) will release first-quarter 2026 financial results and provide a business update after market close on May 19, 2026. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access via the company website.
Investors can join by phone using Conference ID 9329659 or listen on the Events page at www.iridex.com.
Positive
- None.
Negative
- None.
News Market Reaction – IRIX
In the May 6 session, IRIX declined 0.95%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings date notice | Neutral | -2.3% | Set date and call details for Q4 and full-year 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited earnings-date history: the prior notice on Mar 12, 2026 saw a modest -2.26% next-day move.
Over the past months, Iridex reported improving 2025 financials with Q4 revenue of $14.7M, full-year revenue of $52.7M, and a turn to positive adjusted EBITDA. It also announced a headquarters relocation aimed at lowering operating expenses and a retina-laser partnership with EyeProGPO. The current announcement schedules Q1 2026 results for May 19, 2026, echoing the prior earnings-date notice in March that preceded full-year 2025 results.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 9329659. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices, and accessories for the ophthalmology market. The Company’s technologies are used in the treatment of glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
